It seems we can’t find what you’re looking for. Perhaps searching can help.
Nothing found
-
FLASH2 Study opens patient enrollment Princeton, NJ – December 16, 2024 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical [...] -
-
-
-
-
Interview with Suren Ajjarapu, CEO
(OTCQB: TRXD) […] -
-
-
-